Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bioequivalence Data: Statistical Interpretation

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

Pharmacodynamic Models: Overview

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Regression Toward the Mean

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...

Bioequivalence of Drugs: Drugs with Multiple Indications

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multilevel Cervical Disc Arthroplasty: Long-Term Outcomes at 3 and 4 Levels.

International journal of spine surgery·2020

Same author

One-Level Versus 2-Level Treatment With Cervical Disc Arthroplasty or Fusion: Outcomes Up to 7 Years.

International journal of spine surgery·2020

Same author

Lumbar disc arthroplasty versus anterior lumbar interbody fusion: 5-year outcomes for patients in the Maverick disc investigational device exemption study.

Journal of neurosurgery. Spine·2019

Same author

Cervical disc arthroplasty: 10-year outcomes of the Prestige LP cervical disc at a single level.

Journal of neurosurgery. Spine·2019

Same author

Magnetic resonance spectroscopy (MRS) can identify painful lumbar discs and may facilitate improved clinical outcomes of lumbar surgeries for discogenic pain.

European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society·2019

Same author

Treatment of Cervical Myelopathy: Long-term Outcomes of Arthroplasty for Myelopathy Versus Radiculopathy, And Arthroplasty Versus Arthrodesis for Myelopathy.

Clinical spine surgery·2018

Search research articles

Related Experiment Video

Updated: May 15, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Commentary: the proliferation of minimum clinically important differences.

¹Spinal Research Foundation, 1831 Wiehle Ave., Suite 100, Reston, VA 20190, USA. acopay@spinerf.org

The Spine Journal : Official Journal of the North American Spine Society

|January 15, 2013

Summary

This study determined the minimum clinically important difference (MCID) for pain, disability, and quality of life following revision fusion surgery for symptomatic pseudoarthrosis. Findings help interpret patient outcomes after complex spinal procedures.

More Related Videos

Minimal Erythema Dose (MED) Testing

Minimal Erythema Dose (MED) Testing

Published on: May 28, 2013

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Related Experiment Videos

Last Updated: May 15, 2026

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Precision Implementation of Minimal Erythema Dose (MED) Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Minimal Erythema Dose (MED) Testing

Minimal Erythema Dose (MED) Testing

Published on: May 28, 2013

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

Area of Science:

Spine Surgery
Orthopedics
Clinical Outcomes Research

Background:

Symptomatic pseudoarthrosis after spinal fusion presents a significant challenge, often necessitating revision surgery.
Quantifying meaningful changes in patient-reported outcomes is crucial for evaluating the success of revision fusion.
The minimum clinically important difference (MCID) provides a threshold for detecting a relevant improvement in patient well-being.

Purpose of the Study:

To determine the MCID for pain, disability, and quality of life (QOL) after revision fusion for symptomatic pseudoarthrosis.
To establish benchmarks for assessing treatment effectiveness in this challenging patient population.
To guide clinical decision-making and patient expectation management in revision spinal surgery.

Main Methods:

Retrospective analysis of patients undergoing revision fusion for symptomatic pseudoarthrosis.
Utilized validated patient-reported outcome measures for pain, disability, and QOL.
Applied statistical methods to calculate MCID values based on anchor-based and distribution-based approaches.

Main Results:

Specific MCID values were established for pain reduction, functional improvement, and QOL enhancement.
These values represent the smallest change perceived as beneficial by patients post-revision fusion.
Results provide quantitative targets for successful surgical intervention in this cohort.

Conclusions:

The determined MCID values offer critical insights into meaningful recovery after revision fusion for pseudoarthrosis.
These findings aid clinicians in interpreting patient outcomes and setting realistic expectations.
Understanding MCID is essential for advancing the quality of care in complex spinal reconstructive surgery.